

The first groups of volunteers participating in the international phase of clinical trials of the Ad5-nCov vaccine candidate against the SARS-CoV-2 virus, developed by CanSino Biologics Inc., have already been successfully vaccinated. The volunteers are feeling well and none of them has had serious adverse events.


